Background The use of naltrexone plus bupropion to treat methamphetamine use disorder
has not been well studied. Methods We conducted this multisite, double-blind, two-stage …

OBJECTIVE: To compare bupropion to placebo for reducing methamphetamine (MA) use,
increasing retention, and reducing the severity of depressive symptoms and MA-cravings. A …

Bupropion was tested for efficacy in increasing weeks of abstinence in methamphetamine-
dependent patients, compared to placebo. This was a double-blind placebo-controlled …

Aim Bupropion was tested for efficacy to achieve methamphetamine (MA) abstinence in
dependent, non-daily users. Methods A randomized, double-blind, placebo-controlled trial …

Background Methamphetamine use is increasing in parts of the US, yet its impact on
treatment for opioid use disorder is relatively unknown. Methods The study utilized data on …

Background Stimulant (cocaine and/or methamphetamine) use has increased among
people with opioid use disorder. We conducted a systematic review of medications for …

The present study compared in a clinical non-experimental setting the efficacy of
buprenorphine (BUP) and methadone (METH) in the treatment of opioid dependence: all the …

Aims Addiction to methamphetamine/amphetamine (MA/A) is a major public health problem.
Currently there are no pharmacotherapies for MA/A use disorder that have been approved …

Increases in the use of illicit opiates have refocused attention on these drugs. One outgrowth
of this attention has been the increased consideration of pharmacotherapies to provide …

Objective: Currently there is no approved pharmacotherapy for amphetamine dependence.
Recent human laboratory studies have demonstrated that naltrexone modulates some of the …